48237-20-3

Basic information

• Product Name: AMikacin B
• Synonyms: 1-N-[(S)-4-AMino-2-hydroxybutyryl]kanaMycin B;BB-K26;O-3-AMino-3-deoxy-α-D-glucopyranosyl-(1→6)-O-[2,6-diaMino-2,6-dideoxy-α-D-glucopyranosyl-(1→4)]-N1-[(2S)-4-aMino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptaMine;AMikacin B
• CAS NO: 48237-20-3
• Molecular Formula: C22H44N6O12
• Molecular Weight: 584.61776
• Product Categories: Oligosaccharides;Pharmaceuticals;Amines;Impurities;Intermediates & Fine Chemicals
• Mol File: 48237-20-3.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 979.3±65.0 °C(Predicted)
• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• PKA: 13.07±0.70(Predicted)
• CAS DataBase Reference: AMikacin B(CAS DataBase Reference)
• NIST Chemistry Reference: AMikacin B(48237-20-3)
• EPA Substance Registry System: AMikacin B(48237-20-3)

Safety Data

• Hazardous Substances Data: 48237-20-3(Hazardous Substances Data)

Usage

Description

AMikacin B, also known as Amikacin impurity A578500, is a novel aminoglycoside antibiotic derived from the parent compound Amikacin. It possesses potent antimicrobial properties and is characterized by its ability to inhibit bacterial protein synthesis, making it a valuable pharmaceutical candidate for various applications.

Uses

Used in Pharmaceutical Industry:
AMikacin B is used as an antibiotic for the treatment of bacterial infections. Its application is particularly relevant in cases where other conventional antibiotics have shown limited effectiveness or in situations involving multi-drug resistant bacteria. The antibiotic action of AMikacin B helps in combating a wide range of bacterial pathogens, contributing to the overall management and control of infectious diseases.
Used in Research and Development:
In the field of medical research, AMikacin B serves as a valuable compound for studying the mechanisms of antibiotic resistance and the development of new antimicrobial agents. Its unique properties and potential applications make it an important tool in the ongoing efforts to address the global challenge of antibiotic resistance and the need for novel therapeutic options.